Wedbush has initiated coverage on Sarepta Therapeutics Inc (SRPT) with an Outperform rating as of December 8, 2025. The firm’s assessment comes with the current share price at $22.11, marking a significant evaluation of the company's potential in the biotechnology sector.
Sarepta Therapeutics is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focusing on developing therapeutics for rare diseases. The company is actively involved in the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy, and other genetic modalities. It has successfully developed multiple approved products for Duchenne muscular dystrophy (Duchenne) and is advancing a robust pipeline with over 40 programs at various stages of development.
The market capitalization stands at $2.0 billion, with a trailing twelve-month earnings per share (EPS) of -3.35. Upcoming earnings reports are scheduled for May 4, 2026, with an EPS estimate of $0.36 and revenue estimate of $383.2 million, followed by another report on August 4, 2026, projecting an EPS of $0.56 and revenue of $387.2 million.
Analyst ratings serve as a barometer of market sentiment, and while Wedbush’s initiation of coverage indicates a favorable view, it’s essential for investors to consider a range of factors in their decision-making process. Analyst opinions can evolve as new information becomes available, reflecting the dynamic nature of the market.
As of December 1, 2025, analyst consensus on Sarepta Therapeutics includes 7 Strong Buy, 6 Buy, 16 Hold, 4 Sell, and 1 Strong Sell, suggesting a consensus rating of Hold. Recent analyst actions highlight a mix of maintained and upgraded ratings, indicating varied perspectives on the company’s future performance.